Burden of Liver Diseases: A Review from Iran

Amir Anushiravani 1,*, Sadaf Ghajari Sepanlou 1

1. Digestive Disease Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

ABSTRACT

There has been an increase in the burden of liver diseases in Iran, with an increasing trend from communicable to non-communicable diseases. Almost 5400 deaths were due to chronic liver diseases in 2017. We aim to provide a concise update on the epidemiological trends of liver diseases in Iran. Estimations of deaths, disability-adjusted life years, prevalence of chronic liver diseases and cirrhosis in Iran with its common etiologies have been reported. We investigated the major causes of chronic liver diseases in Iran, we have reported our hepatology research centers, and also we have depicted the future of liver diseases in Iran. In 2017, there was a rising trend in chronic liver diseases in Iran. The most common etiologies for chronic liver disease were chronic hepatitis B, chronic hepatitis C, and non-alcoholic steatohepatitis with highest mortalities due to liver cancer and hepatitis C. The prevalence of HBV infection has decreased from 2.9% to 1.3% with effective vaccination, but new cases are still seen due to perinatal transmission. Treatment of HCV has dramatically changed with new drugs which are being produced by local pharmaceuticals at a low cost. The main obstacle in its elimination is finding patients and linkage to care. More than a third of our population have non-alcoholic fatty liver disease in which central obesity had a stronger association than weight itself. Iran has a high burden of liver diseases. The Ministry of Health has effectively controlled hepatitis B and is working towards the World Health WHO’s goals for hepatitis C by 2030. This being said, non-alcoholic fatty liver disease is becoming a major threat to our nation’s health and quality of life.

KEYWORDS: Liver diseases, End-stage liver disease, Liver cirrhosis, Non-alcoholic fatty liver disease, Iran

INTRODUCTION

Liver diseases have been increasing worldwide during the past decades, becoming one of the most common causes of morbidity and mortality. There is an increasing trend in Iran as well.1,2 The Global Burden of Disease (GBD) project showed that almost 5400 deaths due to cirrhosis and other chronic liver diseases occurred in Iran in 2017 (8.12 age-standardized deaths per 100,000). A large number of deaths were premature: almost 20% before the age of 50 and more than half before 70 years of age. In North Africa and the Middle East, Egypt has the highest rate of deaths due to cirrhosis and chronic liver disease (103.32 per 100,000). Turkey had almost the same rate as Iran in 2000 at about 8 per 100,000, but in 2017 their rate became 5.81 age-standardized deaths per 100,000. The trend of deaths due to chronic liver diseases in Saudi Arabia has shown a decline in the last 27 years, but the rates are still high (18.44 per 100,000).2

Even though vaccines have been very effective in controlling hepatitis B virus (HBV) 3 and direct acting antivirals are more than 95% effective in treating hepatitis C virus (HCV), the global burden of cirrhosis and liver diseases are increasing as populations grow and age, and unhealthy life style becomes prevalent.4,5

Studying the trend of diseases at the national level is essential for prioritizing health research and helping policy makers use the evidence based data.
Increased caloric prevention and treatment. Data on trend transmission. Infant prophylaxis and early childhood failure rate of only 5%. Therefore, when we the incidence of new cases in Iran, with a primary vaccination along with Hepatitis B immunoglobulin (HBIG) can prevent this type of transmission, but the latter is expensive and not always available.

The rate of chronic HCV in Iran is estimated to be about 3-5 patients per 1,000 general population. WHO has set goals for 2030: diagnosing at least 90% of patients with viral hepatitis, treating 80%, and reducing its mortality by 65%. To date, we have only been able to diagnose a third of our patients and we have treated merely 3%. In 2014, over 186,000 Iranians had HCV, and with the current diagnosis and treatment levels we expect the number to rise above 210,000 by 2030. Treatment of HCV has dramatically changed after the introduction of direct acting antivirals (DAAs) in 2011, making sustained viral response (SVR) a reality in over 95% with few adverse effects. Currently, local pharmaceuticals are producing DAA with a similar SVR and at a very low cost (less than 100 US$ for a 3-month treatment). The main obstacle in reaching HCV elimination in Iran seems to be finding patients and providing appropriate care and treatment for them. People who use drugs (PWUD) have the highest rates of HCV, 50% in people who inject drugs (PWID) and 12% in those who used drugs within the previous year.

Non-alcoholic fatty liver diseases (NAFLD) has recently become a relatively common cause of chronic liver disease in Iran. A cluster random sampling approach showed a 35.2% prevalence of NAFLD in Iranian adults and central obesity had a stronger association with NAFLD than BMI per se. Increased caloric intake and a sedentary lifestyle are the main risk factors, although genetic variations have been accounted for in almost half of the patients, especially those with lean NAFLD. We estimate that more than a third of the general population have probable NAFLD, being more common in obese, diabetics, and those with the metabolic syndrome. To date, no FDA approved treatment is available for this growing disease.

Alcohol consumption is prohibited by Islam and also by the law, but it is available in the black market. In 2012, the Ministry of Health estimated the rate of alcohol use to be above 2% in the general population and 5% of the young used alcohol for at least once in the preceding year. Therefore, when we
encounter a patient with liver disease, we should always keep alcoholic hepatitis in mind.

**Hepatology Research Institutes in Iran**

The Iranian Association of Gastroenterology and Hepatology (IAGH) has more than 1000 members and is a formal member of the World Gastroenterology Organization (WGO) and holds an annual international congress every autumn. There are 11 established gastroenterology and hepatology research centers throughout the country. Hepatology is one of the most active fields of medical research in Iran, in which scientific output has increased from five papers per year in 1996 to more than 50 in 2007 and over 100 in 2018. Research has mainly been in the fields of viral hepatitis (HBV and HCV), non-alcoholic fatty liver disease, autoimmune liver diseases (autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cholangitis), liver transplant, and stem cell therapy in chronic liver diseases. We were able to collaborate with major universities and the results have been high impact publications in prestigious journals.

**Future of Liver Diseases in Iran**

Iran is the second most populous country in the region with a high burden of liver diseases. Following the impressive efforts to contain HBV and HCV infections by the Ministry of Health, viral hepatitis has been largely controlled. However, NAFLD has emerged as a major threat to health and quality of life in Iran and worldwide.

Due to the growing demand for liver disease research, the scientific association of gastroenterology and hepatology in Iran is planning to make substantial contribution in the field of hepatology with the help of research centers and institutes, to train young scientists, to develop novel drugs, and to establish global collaborations.

**ETHICAL APPROVAL**

There is nothing to be declared.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest related to this work.

**REFERENCES**

1. Sepanlou SG, Malekzadeh F, Naghavi M, Forouzanfar MH, Shahraz S, Moradi-Lakeh M, et al. Trend of Gastrointestinal and Liver Diseases in Iran: Results of the Global Burden of Disease Study, 2010. *Middle East J Dig Dis* 2015;7:121-37.

2. Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington. 2015. Available from http://vizhub.healthdata.org/gbd-compare. (Accessed [September 2019])

3. Teimouri F, Kebriaeezadeh A, Zahraei SM, Gheiratian M, Nikfar S. Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran. *Daru* 2017;25:1. doi: 10.1186/s40199-017-0166-0.

4. Rowe IA. Lessons from Epidemiology: The Burden of Liver Disease. *Dig Dis* 2017;35:304-9. doi: 10.1159/000456580

5. Malekzadeh F, Sepanlou SG, Poustchi H, Naghavi M, Forouzanfar MH, Shahraz S, et al. Burden of Gastrointestinal and Liver Diseases in Iran: Estimates Based on the Global Burden of Disease, Injuries, and Risk Factors Study, 2010. *Middle East J Dig Dis* 2015;7:138-54.

6. Rezaei N, Asadi-Lari M, Sheidaei A, Khademi S, Gohari K, Delavari F, et al. Liver cirrhosis mortality at national and provincial levels in Iran between 1990 and 2010: A meta regression analysis. *Plos one* 2019;14:e0198449. doi: 10.1371/journal.pone.0198449. *eCollection* 2019.

7. Gandomkar A, Poustchi H, Moini M, Moghadami M, Imanieh H, Fatutahi MR, et al. Pars cohort study of non-communicable diseases in Iran: protocol and preliminary results. *Int J Public Health* 2017;62:397-406. doi: 10.1007/s00053-016-0848-2. Epub 2016 Jun 28.

8. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. *Arch Iran Med* 2009;12:225-31.

9. Yao Y, Zhang DG, Guo JT, Qi K, Li F, Zhu JW, et al. A novel self-expanding biliary metal stent vs tubular metal stent for EUS-guided transmural drainage of pancreatic pseudocyst: A retrospective, cohort study. *Medicine* 2019;98: doi: 10.1097/MD.000000000001479.

10. Moghhegh Shalmani H, Noori A, Shokoohi M, Khajavi A, Darvishi M, Delavari A, et al. Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. *Arch Iran Med* 2015;18:508-14. doi: 015188/AIM.008.

11. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Hepatitis B and Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. *Hepat Mon* 2016;16:e37234. doi: 10.5812/hepatmon.37234. *eCollection* 2016 Jul.

12. Alavi M, Poustchi H, Merat S, Kaveh-Ei S, Rahimi-Movaghar A, Shadloo B, et al. An intervention to improve HCV testing, linkage to care, and treatment among people who use drugs in Tehran, Iran: The ENHANCE study. *Int Drug Policy* 2019;72:109-105. doi: 10.1016/j.drugpo.2019.07.002. Epub 2019 Jul 11.

13. Ostovaneh MR, Zamani F, Ansari-Moghaddam A, Sharafkhah M, Saeedian FS, Rohani Z, et al. Nonalcoholic Fatty Liver: The Association with Metabolic Abnormalities, Body Mass Index and Central Obesity—A Population-Based Study. *Metab Syndr Relat Disord* 2015;13:304-11. doi: 10.1089/met.2014.0131. Epub 2015 Jun 4.

14. Modares Mousavi SR, Geramizadeh B, Anushiravani A, Ejtehadi F, Anbardar MH, Moini M. Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. *Middle East J Dig Dis* 2018;10:90-5. doi: 10.15171/mejdd.2018.96. Epub 2018 Mar 12.

15. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaimi A, Alirezae M, et al. Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran. *Int J Organ Transplant Med* 2016;7:49-60.

16. Anushiravani A, Haddradi N, Pourfarmanbar M, Mohamadkarimi V. Treatment options for nonalcoholic fatty liver disease: a double-blinded randomized placebo-controlled trial. *Eur J Gastroenterol Hepatol* 2019;31:613-7. doi: 10.1097/MEG.0000000000001369.

17. Lankarani KB, Afshari R. Alcohol consumption in Iran. *Lancet* 2014;384:1927-8. doi: 10.1016/S0140-6736(14)62279-0.